Literature DB >> 8617960

Identification and characterization of a C(K/R)TC motif as a common epitope present in all subtypes of hepatitis B surface antigen.

X Qiu1, P Schroeder, D Bridon.   

Abstract

The a determinant of hepatitis B surface antigen (HBsAg) is the most critical determinant for both diagnosis and immunoprophylaxis of the hepatitis B virus. We have used synthetic peptides and an anti-a mAb to identify a peptide sequence corresponding to amino acid residues 117 to 128 of HBsAg as an antigenic epitope contributing to the a determinant. Compared to the native protein HBsAg, the cyclic form of the peptide (aa 117-128) is only 20-fold less effective, whereas the linear form of the peptide is 160-fold less effective in the inhibition of mAb binding to HBsAg. Based on these results, we have postulated a previously unidentified disulfide bond between residue Cysl21 and Cysl24. Individual substitution of amino acids in the peptide (aa 117-128) with alanine identified three residues Cys121, Thr123, and Cys124 as the most critical residues for mAb recognition. Substitution of alanine for any one of the three residues caused a substantial loss in binding free energy (greater than 4.5 kcal/mol). Sequence analysis indicated that the C(K/R)TC motif is highly conserved among 100 subtypes and mutants of HBsAg isolates. Collectively, these results show that the cyclic C(K/R)TC motif is an essential part of the a determinant of HBsAg. Synthetic peptides containing the C(K/R)TC motif are potentially useful as alternative hepatitis B vaccines and as diagnostic reagents for the detection of the hepatitis B virus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617960

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  The amino Acid residues at positions 120 to 123 are crucial for the antigenicity of hepatitis B surface antigen.

Authors:  Yongjun Tian; Yang Xu; Zhenhua Zhang; Zhongji Meng; Li Qin; Mengji Lu; Dongliang Yang
Journal:  J Clin Microbiol       Date:  2007-07-03       Impact factor: 5.948

2.  Effects of vaccine-acquired polyclonal anti-HBs antibodies on the prevention of HBV infection of non-vaccine genotypes.

Authors:  Masaki Kato; Susumu Hamada-Tsutsumi; Chiaki Okuse; Aiko Sakai; Nobuyuki Matsumoto; Masaaki Sato; Toshiyuki Sato; Mitsumi Arito; Kazuki Omoteyama; Naoya Suematsu; Kazuki Okamoto; Takanobu Kato; Fumio Itoh; Ryo Sumazaki; Yasuhito Tanaka; Hiroshi Yotsuyanagi; Tomohiro Kato; Manae Suzuki Kurokawa
Journal:  J Gastroenterol       Date:  2017-02-14       Impact factor: 7.527

3.  Porphyrin-mediated binding to hemoglobin by the HA2 domain of cysteine proteinases (gingipains) and hemagglutinins from the periodontal pathogen Porphyromonas gingivalis.

Authors:  A A DeCarlo; M Paramaesvaran; P L Yun; C Collyer; N Hunter
Journal:  J Bacteriol       Date:  1999-06       Impact factor: 3.490

4.  Similarity of recombinant human perlecan domain 1 by alternative expression systems bioactive heterogenous recombinant human perlecan D1.

Authors:  April L Ellis; Wensheng Pan; Guang Yang; Kim Jones; Christine Chuang; John M Whitelock; Arthur A DeCarlo
Journal:  BMC Biotechnol       Date:  2010-09-09       Impact factor: 2.563

5.  Validation of cross-genotype neutralization by hepatitis B virus-specific monoclonal antibodies by in vitro and in vivo infection.

Authors:  Susumu Hamada-Tsutsumi; Etsuko Iio; Tsunamasa Watanabe; Shuko Murakami; Masanori Isogawa; Sayuki Iijima; Takako Inoue; Kayoko Matsunami; Kazuto Tajiri; Tatsuhiko Ozawa; Hiroyuki Kishi; Atsushi Muraguchi; Takashi Joh; Yasuhito Tanaka
Journal:  PLoS One       Date:  2015-02-18       Impact factor: 3.240

6.  Perlecan domain 1 recombinant proteoglycan augments BMP-2 activity and osteogenesis.

Authors:  Arthur A Decarlo; Maria Belousova; April L Ellis; Donald Petersen; Hernan Grenett; Patrick Hardigan; Robert O'Grady; Megan Lord; John M Whitelock
Journal:  BMC Biotechnol       Date:  2012-09-11       Impact factor: 2.563

7.  Detecting hepatitis B surface antigen mutants.

Authors:  Paul F Coleman
Journal:  Emerg Infect Dis       Date:  2006-02       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.